UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2 )*
Cellegy Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
15115L-10-3
-------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C>
SCHEDULE 13G
- ----------------------------------------------- ---------------------------------------------
CUSIP No. 15115L-10-3 Page 2 of 5 Pages
------------------------ ----------- -----------
- ----------------------------------------------- ---------------------------------------------
- --------- --------------------------------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Larry J. Wells
- --------- --------------------------------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [ ]
(b) [X]
- --------- --------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- --------- --------------------------------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
- --------- --------------------------------------------------------------------------------------------------------
5 SOLE VOTING POWER
14,312
NUMBER
OF ------- ------------------------------------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY 399,816*
OWNED
BY ------- ------------------------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 14,312
PERSON
WITH ------- ------------------------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
399,816*
- --------------------------- ------- ------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
414,128
- --------- --------------------------------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
- --------- --------------------------------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.1%
- --------- --------------------------------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
IN
- --------- --------------------------------------------------------------------------------------------------------
<FN>
* Represents 399,816 shares held by Sundance Venture Partners, L.P. of which Anderson & Wells Company is
the General Partner. Larry Wells is Chairman of the Board of Directors of Anderson & Wells Company.
</FN>
</TABLE>
2
<PAGE>
Item 1.
(a) Name of Issuer:
Cellegy Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
1065 East Hillsdale Blvd., Suite 418, Foster City, CA 94404
Item 2.
(a) Name of Person Filing:
Larry J. Wells
(b) Address of Principal Business Office:
10600 N. DeAnza Boulevard, Suite 215, Cupertino, CA 95014
(c) Citizenship:
U.S.A.
(d) Title of Class of Securities:
Common Stock
(e) CUSIP Number:
15115L-10-3
Item 3.
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned:414,128 (includes (i) 9,576 shares
subject to options exercisable within 60 days of December 31,
1997; (ii) a warrant to purchase 4,736 shares; and (iii)
399,816 shares held by Sundance Venture Partners, L.P. in
which Anderson & Wells Company is the General Partner. Larry
Wells is the Chairman of the Board of Directors of Anderson &
Wells Company)
(b) Percent of Class: 4.1%
(c) Number of shares as to which such person has:
(i) sole power to vote or direct the vote: 14,312
(ii) shared power to vote or direct the vote: 399,816
(iii) sole power to dispose or to direct the
disposition of: 14,312
(iv) shared power to dispose or to direct the
disposition of: 399,816
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [x].
3
<PAGE>
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person
Not applicable
Item 7. Identification and Classification of Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below, I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in
any transaction having such purposes or effect.
4
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
2/12/98
- -----------------------------------------------------
Date
/s/ Larry J. Wells
- -----------------------------------------------------
Signature
Larry J. Wells
- -----------------------------------------------------
Name/Title
5
